TENCON Drug Patent Profile

« Back to Dashboard

Which patents cover Tencon, and when can generic versions of Tencon launch?

Tencon is a drug marketed by Mallinckrodt and is included in one NDA.

The generic ingredient in TENCON is acetaminophen; butalbital. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the acetaminophen; butalbital profile page.

Summary for TENCON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	7
DailyMed Link:	TENCON at DailyMed

US Patents and Regulatory Information for TENCON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	TENCON	acetaminophen; butalbital	CAPSULE;ORAL	089405-001	May 15, 1990		DISCN	No	No

Last updated: April 23, 2026

TENCON (tenoxicam): market dynamics and financial trajectory

TENCON is a brand name for tenoxicam, a nonsteroidal anti-inflammatory drug (NSAID). Market dynamics for TENCON are shaped by (1) how tenoxicam is positioned within the NSAID class, (2) national reimbursement and formularies that determine uptake, and (3) competitive pressure from newer NSAIDs, generics, and non-oral pain-management alternatives. Financial trajectory is dominated by patent status and generic entry in each geography, with brand spend and channel strategy determining whether the product behaves like a protected franchise or a price-led generic.

What is TENCON’s market structure and how does it behave?

TENCON’s market behavior is typical of an established NSAID with a mature asset base:

• Product category: NSAID for pain and inflammation (tenoxicam).
• Competitive set: Other NSAIDs (branded and generic), with frequent switching within formulary classes due to perceived class interchangeability.
• Price formation: Strong sensitivity to generic pricing once local exclusivity ends. In markets with high generic penetration, brand pricing compresses and volumes shift toward lower-cost SKUs.

Core demand drivers

• Clinical positioning: Tenoxicam is used for musculoskeletal pain and inflammatory conditions where oral NSAID therapy is standard of care.
• Physician familiarity: Long product presence tends to sustain prescribing, but only until formulary and cost constraints push substitution.
• Local access rules: Listing on reimbursement formularies and restrictions (age, GI risk, co-therapy requirements) govern patient access and daily therapy volumes.

Core demand headwinds

• NSAID class competition: Multiple equivalent molecules and therapeutic alternatives (selective COX-2 inhibitors, topical NSAIDs, combination analgesics) compete for the same patient segment.
• Safety and utilization management: GI risk and cardiovascular risk labeling affects payer and prescriber behavior. Many systems tighten NSAID use through step edits or prefer lower-cost agents with narrower restrictions.
• Generic substitution: Where tenoxicam generics are available, brand-to-generic switching typically accelerates after key exclusivity dates.

How do regulatory and exclusivity timelines shape financial trajectory?

TENCON’s financial path is determined by a geography-specific exclusivity matrix:

• Brand launch and growth phase: Higher margins are possible only while the brand is the dominant marketed version and local exclusivity limits generic substitution.
• Loss of exclusivity: When tenoxicam patents or registrations expire in a country, generic entrants compress pricing.
• Ongoing lifecycle: Even after exclusivity ends, brands can retain partial share through:
  • pack-size and dose differentiation,
  • distribution agreements,
  • perceived tolerability narratives,
  • hospital procurement contracts and established prescribing habits.

In practice, NSAIDs like tenoxicam tend to move from brand-franchise behavior to generic-like economics once generics gain traction in each market.

What market dynamics most influence TENCON’s sales performance?

1) Generic availability and price compression

• Tenoxicam’s long history implies broad generic availability across many regions.
• Brand performance after generic entry usually becomes a volume-share plus price realization story rather than a protected-growth story.

2) Formulary access and reimbursement

• Payers often manage NSAIDs with tiering. If TENCON sits on a higher cost tier than generics, prescriptions shift to lower tiers.
• Where TENCON is preferred or equivalently priced versus competing generics, it can hold share.

3) Substitution within therapeutic class

• Physicians frequently switch among NSAIDs by tolerability, local experience, and patient-specific risk.
• Any brand that maintains consistent supply, dose convenience, and contracting terms can keep a stable base even in crowded markets.

4) Channel and procurement dynamics

• In many healthcare systems, hospital tenders and pharmacy procurement heavily influence which NSAIDs are stocked.
• Once procurement standardizes around low-cost SKUs, brand volumes decline.

What does TENCON’s financial trajectory look like under typical NSAID economics?

TENCON’s financial trajectory usually follows one of two patterns depending on geography:

Pattern A: Post-exclusivity pricing compression

• Revenue: Declines or stagnates due to lower net price.
• Margins: Compress sharply as brand discounts and rebates rise or as generic substitution reduces brand share.
• Share: Either falls steadily or plateaus at a “loyal base” tied to clinician habit and payer tiering.

Pattern B: Residual brand strength in limited territories

• Revenue: Holds better when:
  • brand remains price-competitive versus generics, or
  • reimbursement positioning is favorable, or
  • distribution agreements protect shelf space.
• Margins: Still typically mean-reverting toward generic levels unless the brand differentiates materially in packaging, dosing regimen, or contracting terms.

Without geography-specific financial disclosures for the specific TENCON brand entity, a precise sales and profit forecast cannot be stated in numeric terms. The financial trajectory for TENCON across markets is therefore expected to be dominated by generic economics and payer access rather than by new clinical differentiation.

How does TENCON compare with key competitive forces in NSAIDs?

Competitive variables that determine share movement

• Net price versus nearest generic: Drives switch probability.
• Formulary status (preferred vs non-preferred): Governs where prescriptions land.
• Safety-related prescribing constraints: Influences patient selection, especially in older cohorts.
• Alternative dosage forms and routes: Topicals can displace oral NSAIDs for certain indications.

Typical outcome in mature NSAID markets

• Competitive pressure pushes brands toward:
  • stable contracted volume,
  • targeted segments (where prescriber habit persists),
  • SKU rationalization to protect pricing.

What regulatory and safety factors can affect market access?

TENCON contains tenoxicam, an NSAID. Like other NSAIDs, it is subject to:

• labeling and risk communications for GI and cardiovascular risk,
• age-related restrictions in some systems,
• restrictions for patients with prior ulceration or concomitant anticoagulants.

These factors do not eliminate demand, but they affect:

• payer authorization rules,
• prescriber selection,
• patient persistence.

What would be the investment-relevant “watch items” for TENCON-type assets?

For business or investment decisions, the core measurable items are:

• Country-by-country generic share and branded net price index
• Formulary tier movement (preferred vs non-preferred changes)
• Tender or procurement outcomes in hospital segments
• Inventory and supply stability impacting realized volume
• Switch-back signals if a brand maintains favorable net pricing after competitors enter

These are the levers that determine whether TENCON behaves like a fading brand or holds stable revenue in pockets.

Key Takeaways

• TENCON (tenoxicam) operates in a mature NSAID market where generic substitution and formulary access drive revenue and margin outcomes.
• Financial trajectory is primarily pricing-led after exclusivity, with share retention dependent on payer tiering, contracting, and channel stability rather than clinical differentiation.
• Market dynamics track the standard NSAID pattern: class competition, reimbursement tiering, and safety-based utilization management decide whether a brand plateaus or declines after generic entry.

FAQs

1. Is TENCON protected by ongoing exclusivity globally?
   TENCON’s tenoxicam active is a mature molecule, so exclusivity and generic entry outcomes are geography-specific; in most markets the brand typically shifts into generic economics once local exclusivity ends.

2. What drives TENCON sales most after generic entry?
   Net price versus competing generics, formulary tier placement, and hospital procurement contracts.

3. Do NSAID safety communications materially reduce demand for tenoxicam?
   They can constrain utilization for higher-risk patients, but they usually shift prescribing patterns within the NSAID class rather than eliminating NSAID use.

4. How does formulary positioning affect TENCON volume?
   Preferred placement and favorable reimbursement reduce patient-switch probability; non-preferred placement increases switching to lower-cost alternatives.

5. What is the most useful metric set for tracking TENCON financial trajectory?
   Branded net price trends, branded share versus generics by channel, and changes in formulary or tender status.

References

[1] PubChem. Tenoxicam. https://pubchem.ncbi.nlm.nih.gov/compound/Tenoxicam
[2] DailyMed. Tenoxicam (drug label information). https://dailymed.nlm.nih.gov/